Edgewise Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	42.28	40.02	31.87	23.45	17.63	11.03
Research & Development	157.28	151.39	126.97	90.91	54.03	32.19
Total Operating Expenses	199.56	191.41	158.83	114.36	71.66	43.22
Operating Income	-199.56	-191.41	-158.83	-114.36	-71.66	-43.22
Interest Income	23.55	23.61	25.02	14.19	4.02	0.4
Total Non-Operating Income (Expense)	23.55	23.61	25.02	14.19	4.02	0.4
Pretax Income	-176.01	-167.8	-133.81	-100.16	-67.64	-42.81
Net Income	-176.01	-167.8	-133.81	-100.16	-67.64	-42.81
Net Income to Common	-176.01	-167.8	-133.81	-100.16	-67.64	-42.81
Shares Outstanding (Basic)	106	103	92	64	54	38
Shares Outstanding (Diluted)	106	103	92	64	54	38
Shares Change (YoY)	12.30%	11.38%	45.02%	18.90%	42.82%	-
EPS (Basic)	-1.66	-1.63	-1.45	-1.57	-1.26	-1.14
EPS (Diluted)	-1.66	-1.63	-1.45	-1.57	-1.26	-1.14
Shares Outstanding	107.48	106.25	94.84	70.45	63.26	49.5
Free Cash Flow	-148.97	-144.07	-110.34	-97.69	-58.18	-34.18
Free Cash Flow Per Share	-1.41	-1.40	-1.19	-1.53	-1.09	-0.91
EBITDA	-197.26	-189.14	-156.54	-112.63	-71.12	-42.94
EBIT	-199.56	-191.41	-158.83	-114.36	-71.66	-43.22

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q